WGO Graded Evidence: Strategies for Reducing the Prevalence of Antimicrobial Resistance

Level: Clinical Trials: 20 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Helicobacter pylori eradication with a capsule containing bismuth subcitratepotassium, metronidazole, and tetracycline given with omeprazole versusclarithromycin-based triple therapy: a randomised, open-label, non-inferiority,phase 3 trial. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M,Mégraud F; Pylera Study Group., Lancet. 2011 Mar 12;377(9769):905-13. Epub 2011 Feb 21.
	No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K., Hepatology. 2011 Mar;53(3):763-73. doi: 10.1002/hep.24078. Epub 2010 Dec 22.
	Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2bplus ribavirin in chronic hepatitis C. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M., Gastroenterology. 2010 Jan;138(1):108-15. Epub 2009 Sep 18.
	Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2bplus ribavirin for treating chronic hepatitis C virus infection. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG,Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G., Gastroenterology. 2010 Jan;138(1):116-22. Epub 2009 Oct 20.
	Use of procalcitonin to reduce patients' exposure to antibiotics in intensivecare units (PRORATA trial): a multicentre randomised controlled trial. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F,Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C,Chastre J, Wolff M; PRORATA trial group., Lancet. 2010 Feb 6;375(9713):463-74. Epub 2010 Jan 25.
	Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. I Rapti, E Dimou, P Mitsoula, SJ Hadziyannis, Hepatology. 2007 Feb:307-13
	Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group, Hepatology. 2008 Jul;48(1):99-108
	Intervention to reduce transmission of resistant bacteria in intensive care. Huskins WC, Huckabee CM, O'Grady NP, Murray P, Kopetskie H, Zimmer L, Walker ME, Sinkowitz-Cochran RL, Jernigan JA, Samore M, Wallace D, Goldmann DA; STAR*ICUTrial Investigators., N Engl J Med. 2011 Apr 14;364(15):1407-18.
	Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity inpatients with genotype 1 chronic hepatitis C. Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, Voitot H,Vidaud M, Seiwert S, Bradford B, Zeuzem S, Marcellin P., Gut. 2010 Dec;59(12):1694-8. Epub 2010 Sep 21.
	Empirical levofloxacin-containing versus clarithromycin-containing sequentialtherapy for Helicobacter pylori eradication: a randomised trial. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A,Salerno R, Marmo R, Federico A, Nardone G., Gut. 2010 Nov;59(11):1465-70.
	Empirical levofloxacin-containing versus clarithromycin-containing sequentialtherapy for Helicobacter pylori eradication: a randomised trial. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A,Salerno R, Marmo R, Federico A, Nardone G., Gut. 2010 Nov;59(11):1465-70.
	Sequential and concomitant therapy with four drugs is equally effective foreradication of H pylori infection. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY., Clin Gastroenterol Hepatol. 2010 Jan;8(1):36-41.e1. Epub 2009 Oct 3.
	Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and4 patients with slow virologic response. Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M,Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K,Steindl-Munda P; Austrian Hepatitis Study Group., Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. Epub 2009 Nov 10.
	Race, insulin resistance and hepatic steatosis in chronic hepatitis C. HS Conjeevaram, DE Kleiner, JE Everhart, JH Hoofnagle, S Zacks, NH Afdhal, AS Wahed, Virahep-C Study Group, Hepatology. 2007 Jan:80-7
	Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacterpylori: a clinical trial. Cammarota G, Branca G, Ardito F, Sanguinetti M, Ianiro G, Cianci R, Torelli R,Masala G, Gasbarrini A, Fadda G, Landolfi R, Gasbarrini G., Clin Gastroenterol Hepatol. 2010 Sep;8(9):817-820.e3. Epub 2010 May 31.
	Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Kuo CH, Wang SS, Hsu WH, Kuo FC, Weng BC, Li CJ, Hsu PI, Chen A, Hung WC, YangYC, Wang WM, Wu DC., Helicobacter. 2010 Aug;15(4):265-72.
	Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Filipec Kanizaj T, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S, Helicobacter. 2009 Feb;14(1):29-35
	Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. S Miehlke, K Hansky, W Schneider-Brachert, C Kirsch, A Morgner, A Madisch, E Kuhlisch, E Bæstlein, E Jacobs, E Bayerd&oeig;rffer, N Lehn, M Stolte, Aliment Pharmacol Ther. 2006 Jul 15:395-403
Supplementary evidence:
	Antimicrobial resistance associated with the treatment of bacterial vaginosis. RH Beigi, MN Austin, LA Meyn, MA Krohn, SL Hillier, Am J Obstet Gynecol. 2004 Oct:1124-9
	First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. TT Koivisto, HI Rautelin, ME Voutilainen, MT Heikkinen, JP Koskenpato, MA Færkkilæ, Aliment Pharmacol Ther. 2005 Mar 15:773-82